Table 1.
Participants’ characteristics. Data presented as mean ± SD unless stated otherwise
| Total | BCa | PCa | |
|---|---|---|---|
| n | 40 | 20 | 20 |
| Age | 62.9 ± 9.2 | 58.4 ± 9.7 | 67.5 ± 6.0 |
| BMI (kg/m2) | 27.4 ± 3.9 | 27.1 ± 4.8 | 27.7 ± 2.7 |
| Time since diagnosis (months) | 20.8 ± 29.1 | 9.7 ± 3.5 | 32.0 ± 38.2 |
| Time since end of primary treatment† (months) | 3.6 ± 2.4 | 3.5 ± 2.0 | 3.8 ± 2.7 |
| Type of treatment received, n (%) | |||
| Surgery | 36 (90) | 20 (100) | 16 (80) |
| Chemotherapy | 10 (25) | 10 (50) | 0 (0) |
| Radiation | 32 (80) | 18 (90) | 14 (70) |
| Antihormonal therapy‡ | 23 (58) | 17 (85) | 6 (30) |
| Current ß-blocker intake, n (%) | 11 (28) | 5 (13) | 6 (15) |
| VO2peak (mL/min/kg), n | 19.7 ± 4.1, 39 | 19.2 ± 3.4, 20 | 20.3 ± 4.7, 19 |
| PPO (W/kg) | 1.6 ± 0.4 | 1.5 ± 0.3 | 1.7 ± 0.4 |
BMI, body mass index; BCa, breast cancer patients; PPO, peak power output; PCa, prostate cancer patients; SD, standard deviation; VO2peak, peak oxygen consumption
†Surgery and/or radiotherapy and/or chemotherapy
‡21 of 23 participants were still undergoing antihormonal therapy at the beginning of the study